The possibility of diameter optimization of ZnO nanowires by using statistical design of experiment (DoE) is investigated. In this study, nanowires were synthesized using a vapor–liquid–solid (VLS) growth method in a horizontal reactor. The effects of six synthesis parameters (synthesis time, synthesis temperature, thickness of gold layer, distance between ZnO holder and substrate, mass of ZnO and Ar flow rate) on the average diameter of a ZnO nanowire were examined using the fractional factorial design (FFD) coupled with response surface methodology (RSM). Using a 2III6−3 FFD, the main effects of the thickness of the gold layer, synthesis temperature and synthesis time were concluded to be the key factors influencing the diameter. Then Box–Behnken design (BBD) was exploited to create a response surface from the main factors. The total number of required runs for the DoE process is 25, 8 runs for FFD parameter screening and 17 runs for the response surface obtained by BBD. Three extra runs are done to confirm the predicted results.

No abstract

Background Special attention has been recently paid to the expression of the SOX10 marker, which is actually responsible for coordinating the signaling process of the Wnt/B-catenin evolutionary pathway and therefore responsible for cell proliferation and differentiation in tumor cells. We aimed to study the expression of this marker in different types of gastric adenocarcinomas and to find its relationship with histopathologic features of the tumor. Methods This cross-sectional study was performed on patients with gastric adenocarcinoma (diffuse or intestinal type) whose malignancy could be confirmed by tissue. Subjects were classified according to CAP criteria based on pathology results. Patients underwent immunohistochemical staining to evaluate SOX10 expression. Tumor behavior was determined based on histological studies. Results SOX10 positivity was reported in 22.5% of all tissue samples assessed. The assessment of relationship between SOX10 expression and baseline and tumor characteristics showed no significant association of SOX10 expression and patients’ gender, age, tumor location, tumor size, its type and also lymphovascular and perineural invasions. Conclusion The expression of the SOX10 marker is expected only in 22.5% of patients diagnosed with gastric cancer. In our society, the expression of this marker has nothing to do with the biological and aggressive behaviors of this tumor. Highlights

No abstract

No abstract

No abstract

No abstract

No abstract